Is the new drug Hadlima approved for treating rheumatoid arthritis?
Hadlima is a brand name for adalimumab, a tumor necrosis factor (TNF) blocker. The U.S. Food and Drug Administration (FDA) has approved Hadlima for several inflammatory conditions, including rheumatoid arthritis (RA). Specifically, it is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adults with moderately to severely active RA 3.
What the research says
The FDA approval for Hadlima in RA is based on clinical trials that demonstrated its effectiveness in reducing joint pain and swelling, slowing joint damage, and improving physical function 3. It is one of several TNF blockers available for RA. While the sources provided do not include specific trial data for Hadlima, the approval information confirms its use for RA 3. Other sources in this set discuss different aspects of RA, such as infection risk 1, alternative treatments like plant-derived extracellular vesicles 2 or sinomenine 4, and care models 7, but they do not directly address Hadlima's approval or efficacy.
What to ask your doctor
- Is Hadlima (adalimumab) a good option for my level of rheumatoid arthritis activity?
- What are the potential side effects of Hadlima, especially the risk of infections like herpes zoster?
- How does Hadlima compare to other TNF blockers or non-TNF treatments for RA?
- Will I need any lab tests or vaccinations before starting Hadlima?
- How is Hadlima administered, and how often will I need treatment?
This question is drawn from common patient questions about Rheumatology and answered using cited medical research. We do not provide individualized advice.